Barnes Dennig Private Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Barnes Dennig Private Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49K	Hold	3	–	–	﹤0.01%	309
2026 Q1	$1.34K	Hold	3	–	–	﹤0.01%	292
2025 Q4	$1.36K	Buy	+3	New	+$1.29K	﹤0.01%	295
2025 Q3	–	Sell	-251	Closed	-$112K	–	339
2025 Q2	$112K	Buy	251 +223	+796%	+$103K	0.13%	90
2025 Q1	$13.6K	Buy	+28	New	+$13K	0.02%	117

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Barnes Dennig Private Wealth Management's VRTX Position: Q2 2026 in Review

Barnes Dennig Private Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 3 shares worth $1.49K. The position accounts for ﹤0.01% of the portfolio, ranked #309.

Barnes Dennig Private Wealth Management first reported a position in VRTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $112K in Q2 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Barnes Dennig Private Wealth Management held 3 shares of Vertex Pharmaceuticals worth $1.49K as of Q2 2026.
Barnes Dennig Private Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Barnes Dennig Private Wealth Management's portfolio in Q2 2026, its #309 holding.
Barnes Dennig Private Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
Barnes Dennig Private Wealth Management's Vertex Pharmaceuticals position peaked at $112K in Q2 2025.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Barnes Dennig Private Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.